Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc > New Article

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 01, 2022 11:26am

145 Views

Post# 35143141

RE:RE:New Article

CEO buys another $16,720 worth of stock further adding to his recent buys.

$16,720
+15,200 vol
$1.10 each

prophetoffactz wrote: The CEO has now bought >$71,000 worth of shares in recent months having added another $11,000 last Friday.

prophetoffactz wrote: As the CEO continues to buy shares here's a new article suggesting why. Some of the top clinicians in the world are involved with a study about to commence in Q4. Approval could be a game-changer. MPH has already received a Priority Review Voucher that could be worth US$100-US$200 million.

Pg. 20:
Insights Magazine - BIOTECanada (biotech.ca)